Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18246158 | 1.00 | APLNR (1.00) | APLNR | |
| SCHEMBL18246529 | 1.00 | APLNR (1.00) | APLNR | |
| SCHEMBL18247250 | 1.00 | APLNR (1.00) | APLNR | |
| SCHEMBL30134657 | 1.00 | APLNR (1.00) | APLNR | |
| SCHEMBL21748033 | 1.00 | APLNR (1.00) | APLNR | |
| SCHEMBL29219033 | 1.00 | APLNR (1.00) | APLNR | |
| SCHEMBL18492882 | 0.95 | APLNR (1.00) | APLNR | |
| SCHEMBL18246358 | 0.95 | APLNR (1.00) | APLNR | |
| SCHEMBL18246921 | 0.95 | APLNR (1.00) | APLNR | |
| SCHEMBL21097425 | 0.94 | APLNR (1.00) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3300500-B9 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2021-01-13 | — | — | EP | claimed |
| CN-108137545-B | Triazole agonists of the APJ receptor | 美国安进公司 | 2020-09-22 | — | — | CN | claimed |
| EP-3300500-B1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2020-02-26 | — | — | EP | claimed |
| US-10058550-B2 | Methods of treating heart failure | AMGEN INC. (US) | 2018-08-28 | — | — | US | claimed |
| EP-3300500-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | Amgen Inc. (US) | 2018-04-04 | — | — | EP | claimed |
| US-9868721-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2018-01-16 | — | — | US | claimed |
| US-20170281625-A1 | METHODS OF TREATING HEART FAILURE | AMGEN INC. | 2017-10-05 | — | — | US | claimed |
| US-9751864-B2 | Methods for preparing triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-09-05 | — | — | US | claimed |
| US-9745286-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-08-29 | — | — | US | claimed |
| US-9656997-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-05-23 | — | — | US | claimed |
| US-9573936-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-02-21 | — | — | US | claimed |
| US-20170044131-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-16 | — | — | US | claimed |
| US-20170042872-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-16 | — | — | US | claimed |
| US-20170042871-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-16 | — | — | US | claimed |
| US-20170037026-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-09 | — | — | US | claimed |
| WO-2016187308-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2016-11-24 | — | — | WO | claimed |
| US-20160340336-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2016-11-24 | — | — | US | claimed |
| US-20240366602-A1 | COMBINATION THERAPY OF APELIN RECEPTOR AGONIST AND GLP-1 RECEPTOR AGONIST FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH WEIGHT GAIN | BioAge Labs, Inc. | 2024-11-07 | — | — | US | disclosed |
| WO-2016187308-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2016-11-24 | — | — | WO | disclosed |
| WO-2016187308-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2016-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170042871-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | APLNR 4/4885 |
| US-20170044131-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | APLNR 4/4885 |
| US-20170042872-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | APLNR 4/4885 |
| US-20240366602-A1 | COMBINATION THERAPY OF APELIN RECEPTOR AGONIST AND GLP-1 RECEPTOR AGONIST FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH WEIGHT GAIN | APLNR, GLP1R, GIPR | APLNR 1/4885 |
| US-10058550-B2 | Methods of treating heart failure | FABP3, TNNI3, APLNR | APLNR 3/4885 |
| US-20170037026-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | APLNR 4/4885 |
| US-20170281625-A1 | METHODS OF TREATING HEART FAILURE | FABP3, TNNI3, APLNR | APLNR 3/4885 |
| US-20160340336-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | APLNR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.